Company InnoCan Pharma Corporation

INNO

CA45783P5085

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 18:44:26 10/06/2026 BST			5-day change	1st Jan Change
3.600 ^CAD	0.00%		+5.88%	-46.27%

05-27	InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-06	Innocan Pharma Corporation Is Featured for Liposomal Delivery Platform for Synthetic Cannabidiol in Pain Medicine News	CI

Business description: InnoCan Pharma Corporation

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Sales by Activity: InnoCan Pharma Corporation

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Online Sales	-	-	13.55M	29.4M	26.6M
Other Operations	-	-	109K	38K	15K
Pharmaceuticals	196K	2.56M	-	-	-

See all business segments

Geographical breakdown of sales: InnoCan Pharma Corporation

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	34K	2.42M	13.55M	29.4M	26.6M
Rest of The World	41K	59K	109K	38K	15K
United Kingdom	-	83K	-	-	-
Poland	60K	-	-	-	-
France	61K	-	-	-	-

See all geographic segments

Executive Committee: InnoCan Pharma Corporation

Manager	Title	Age	Since
Nir Avram CTO	Chief Tech/Sci/R&D Officer	73	30/09/2017
Iris Bincovich CEO	Chief Executive Officer	-	30/05/2018
Nelson Halpern DFI	Director of Finance/CFO	-	19/02/2019
Eyal Kalo CTO	Chief Tech/Sci/R&D Officer	-	30/04/2023
Roni Kamhi COO	Chief Operating Officer	-	10/08/2022

See INNOCAN PHARMA CORPORATION governance

Composition of the Board of Directors: InnoCan Pharma Corporation

Director	Title	Age	Since
Iris Bincovich CHM	Chairman	-	30/06/2025
Ralph Bossino BRD	Director/Board Member	-	29/09/2019
Joshua Lintern BRD	Director/Board Member	39	29/09/2019
Eyal Flom BRD	Director/Board Member	61	24/09/2019
Peter Bloch BRD	Director/Board Member	66	21/01/2020
Roni Kamhi BRD	Director/Board Member	-	-

Composition of the Board of Directors

Shareholders: InnoCan Pharma Corporation

Name	Stocks	%	Valuation
Solsken Ltd. 17.01 %	765,039	17.01 %	2 M $
Ron Abraham Mayron 2.306 %	103,746	2.306 %	280 633 $
Iris Bincovich 1.841 %	82,826	1.841 %	224 044 $
Eyal Flom 0.9339 %	42,014	0.9339 %	113 648 $
Roni Kamhi 0.228 %	10,257	0.228 %	27 745 $

List of INNOCAN PHARMA CORPORATION shareholders

Company details: InnoCan Pharma Corporation

InnoCan Pharma Corp.

926-5th Avenue SW

T2P 0N7, Calgary

+403-777-1519

http://www.innocanpharma.com

address InnoCan Pharma Corporation(INNO)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INNOCAN PHARMA CORPORATION	0.00%	+5.88%	-65.38%	-74.24%	11.63M
ELI LILLY AND COMPANY	+2.62%	+3.71%	+44.32%	+162.07%	1,013B
JOHNSON & JOHNSON	+0.86%	+5.51%	+55.06%	+50.56%	574B
ABBVIE INC.	+0.59%	+0.64%	+18.21%	+64.37%	397B
ROCHE HOLDING AG	-0.37%	+4.97%	+21.24%	+15.95%	324B
ASTRAZENECA PLC	+0.81%	+0.21%	+24.54%	+14.81%	280B
NOVARTIS AG	+2.07%	+5.23%	+25.67%	+34.19%	273B
AMGEN INC.	+3.35%	+0.96%	+19.57%	+60.53%	182B
NOVO NORDISK A/S	-0.19%	-0.46%	-45.32%	-48.35%	194B
GILEAD SCIENCES, INC.	+3.47%	-2.42%	+15.32%	+61.89%	151B
Average	+1.31%	+2.97%	+11.32%	+34.18%	338.87B
Weighted average by Cap.	+1.49%	+3.99%	+29.98%	+73.32%